Search the Newsreel

Versamet Royalties (VMET) Earnings Date and Reports 2026

Versamet Royalties (VMET) announced its Q2 2026 earnings on August 13, 2026, reporting an EPS of $0.04, missing analysts' consensus estimate of $0.06. The company's quarterly revenue was $23.73 million. VMET's earnings are projected to grow by 48.00% next year, from $0.25 to $0.37 …

Versamet reports Q2 revenue surge to $23.7M and net income jump to $4.9M, driven by record gold equivalent ounces.

Versamet Royalties Corporation announced a strong Q2 2026 with revenue surging to $23.7 million and net income jumping to $4.9 million, representing increases of 392% and 2,781% respectively, year-over-year. This growth was primarily driven by a record 5,255 gold equivalent ounces (GEOs) produced, a …

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Versamet posts Q2 revenue of $23.7M, up 392% year-over-year

Versamet Royalties Corporation announced Q2 2026 revenue of $23.7 million, a 392% year-over-year increase, driven by a 256% rise in attributable gold equivalent ounces. The company reported a net income of $4.9 million and an adjusted EBITDA of $18.8 million, significantly up from the …

Gossamer Bio earnings beat by $0.04, revenue topped estimates

Versamet (VMET) boosts revenue to $23.7M and closes $360M Eskay Creek stream

Versamet Royalties Corporation reported significantly higher revenues of $23.7 million in Q2 2026, up from $4.8 million a year prior, driven by an expanded portfolio and stronger commodity prices. The company also announced the acquisition of the Eskay Creek Gold Stream for $360 million, …

Earnings Flash (VMET) Versamet Royalties Corporation Reports Q2 Revenue $23.7M, vs. FactSet Est of $33.8M

Gossamer Bio: Q2 Earnings Snapshot

Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain

Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary

Gossamer Bio, Inc. reported its current quarter 2026 financial results, showing revenue of $9.24 million and a net income of $16.9 million, a significant improvement from a net loss in the prior year. The company also highlighted positive Phase 3 clinical trial results for …

Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates

Gossamer Bio Inc (GOSS) recently reported its Q2 2026 financial results, showing a loss but exceeding revenue estimates. The company, a clinical-stage biopharmaceutical firm, is focusing on developing seralutinib for pulmonary arterial hypertension. Several legal firms are investigating the company, and its stock has …

CrossAmerica Partners LP (CAPL) Hits Fresh High: Is There Still Room to Run?

A strong stock as of late has been CrossAmerica Partners (CAPL). Shares have been marching higher, with the stock up 4% over the past month. The stock hit a new 52-week high of $23.48 in the previous session. CrossAmerica has gained 13.1% since the …

Black Sesame International Holding (SEHK:2533) Issues H1 2026 Guidance, Is The Valuation Already Full?

GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS)

CrossAmerica reports lower second-quarter 2026 net income

CrossAmerica Partners LP reported a net income of $20.8 million for the second quarter of 2026, a decrease from $25.2 million in the same period of 2025. Despite the lower net income, the fuel distributor and convenience-store operator saw an increase in adjusted EBITDA, …

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Gossamer Bio, Inc. (GOSS) breached their fiduciary duties due to alleged misrepresentations about its Phase 3 PROSERA study. The lawsuit claims the company failed to disclose issues with the study's design, leading to artificially inflated …

CrossAmerica Partners LP Up Nearly 6%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk

CrossAmerica Partners LP (CAPL) stock is currently up almost 6%, poised for its most significant percentage increase since April 2023. This surge follows a consecutive streak of seven trading days where the stock saw losses.

Why (CAPL) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Crossamerica Partners Lp (NASDAQ: CAPL), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It identifies key support and resistance levels, offering three distinct AI-generated trading strategies with specific entry, target, and stop-loss zones for …

Versamet Royalties Ord Shs (VMET) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Versamet Royalties Ord Shs (VMET), noting a market capitalization of $1.08 billion and a P/E TTM of 30.34. Based on 5 analysts, the stock has a "Buy" rating with a target price of $18.800, representing a 92.82% …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ: GOSS) securities. The investigation focuses on whether Gossamer and its officers engaged in corporate wrongdoing. The firm encourages investors who bought Gossamer shares before June 16, …

Versamet Royalties Ord Shs (VMET) Stock News Today

CrossAmerica Partners LP Common Units 2026 Q2 - Results - Earnings Call Presentation (NYSE:CAPL) 2026-08-07

Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Gossamer Bio Inc (GOSS) has an earnings forecast score of 6.50, ranking 325 out of 387 in its industry, with an average price target of $9.00 based on 8 analysts. The market expects the company's revenue for the next quarter to be $5.19M and …

Earnings call transcript: CrossAmerica beats Q2 2026 estimates as cash flow jumps

CrossAmerica Partners significantly surpassed Q2 2026 earnings and revenue estimates, reporting $0.52 EPS against a $0.21 forecast and $1.18 billion in revenue versus $770.63 million expected. This strong performance was driven by improved fuel margins, merchandise sales, and rigorous cost control, leading to a …

CAPL: Adjusted EBITDA surged 40% year-over-year, with improved margins and lower expenses

CrossAmerica Partners LP (CAPL) reported a 40% year-over-year surge in Adjusted EBITDA to $51.8 million, driven by strong fuel margins and merchandise performance. The company also saw operating expenses decline for the seventh consecutive quarter and improved leverage and coverage ratios. Despite these gains, …

CrossAmerica Partners LP Reports Second Quarter 2026 Results

CrossAmerica Partners LP announced its second quarter 2026 financial results, reporting significant growth in Adjusted EBITDA of $51.8 million and Distributable Cash Flow of $33.6 million compared to the same period in 2025. The Partnership's retail segment gross profit increased by 13% and the …

Crossamerica Partners LP earnings beat by $0.31, revenue topped estimates

Crossamerica Partners LP reported strong second-quarter results, with EPS of $0.52 significantly beating analyst estimates of $0.21. The company's revenue also topped expectations, coming in at $1.18 billion against a consensus of $770.63 million. Despite recent stock fluctuations, the company has seen positive performance …

CrossAmerica Partners LP Reports Second Quarter 2026 Results; Raises Adjusted EBITDA and Distributable Cash Flow, Declares Quarterly Distribution

CrossAmerica Partners LP announced its second quarter 2026 financial results, reporting significant growth in Adjusted EBITDA of $51.8 million and Distributable Cash Flow of $33.6 million compared to the same period in 2025. The Partnership's retail segment gross profit increased by 13% and the …

CrossAmerica declares $0.525 quarterly payout after Q2 results

CrossAmerica Partners (NYSE:CAPL) Releases Quarterly Earnings Results

VMET|Versamet Royalties Ord Shs|Price:9.210|Chg%:+0.380

Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. (NASDAQ:GOSS) on behalf of investors who purchased securities prior to June 16, 2025, and still hold them. The investigation focuses on whether Gossamer's officers and/or directors engaged in corporate wrongdoing. The …

CrossAmerica Partners (NYSE:CAPL) Trading Down 3.9% - Here's Why

CrossAmerica Partners (NYSE:CAPL) saw its share price drop by 3.9% to $21.3450, with trading volume significantly below average. This decline comes despite the company exceeding expectations in its latest quarterly results, reporting $0.26 EPS against an anticipated loss and revenues of $841.83 million. Analysts …